文献速递心律失常冠心病

AUGUSTUS试验:房颤合并急性冠脉综合征或PCI后,阿哌沙班与维生素K拮抗剂及阿司匹林与安慰剂按肾功能分层的获益风险分析

Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
PubMed 文献 · Circulation · 2021-01-19

AUGUSTUS试验纳入4456例房颤合并急性冠脉综合征或经皮冠状动脉介入治疗且接受P2Y12抑制剂的患者,按基线eGFR分层分析。与维生素K拮抗剂相比,阿哌沙班在各eGFR类别均降低出血、死亡或住院及缺血事件风险,无显著交互作用;阿司匹林较安慰剂在所有eGFR类别均增加出血风险,eGFR>80者增幅更显著。

要点

  • 阿哌沙班较维生素K拮抗剂在各肾功能类别均降低出血、死亡或住院及缺血事件,安全性疗效一致。
  • 阿司匹林较安慰剂在所有肾功能类别均增加出血风险,eGFR>80者交互作用显著。
  • 阿司匹林与安慰剂在死亡或住院及缺血事件方面各eGFR类别风险相当。

核心结论

  • 与华法林相比,阿哌沙班的安全性和疗效不因肾功能而异,与总体试验结果一致。
  • 阿司匹林在所有肾功能类别均一致增加出血风险。

研究设计与样本

  • AUGUSTUS试验为开放标签、2×2析因、随机对照临床试验,共纳入4456例房颤合并急性冠脉综合征或经皮冠状动脉介入治疗的患者。
  • 使用CKD-EPI公式计算基线eGFR,按肾功能类别用Cox模型评估阿哌沙班与维生素K拮抗剂及阿司匹林与安慰剂的效应。
  • 主要结局为ISTH大出血或临床相关非大出血;次要结局包括死亡或住院及缺血事件。
  • 肌酐清除率<30 mL/min为AUGUSTUS试验排除标准。

主要发现

  • 30%、52%、19%的患者eGFR分别为>80、>50至80、30至50 mL·min-1·1.73 m-2。
  • 6个月随访时共发生543例主要出血结局、1125例死亡或住院、282例缺血事件。
  • 与维生素K拮抗剂相比,阿哌沙班组所有3种结局在多数eGFR类别发生率更低,无显著交互作用。
  • 阿哌沙班在eGFR 30至50 mL·min-1·1.73 m-2者出血绝对风险降低最显著,发生率为13.1%对21.3%(HR 0.59;95%CI 0.41-0.84)。
  • 阿司匹林组所有eGFR类别出血风险更高,eGFR>80 mL·min-1·1.73 m-2者增幅更大:16.6%对5.6%(HR 3.22;95%CI 2.19-4.74;交互作用P=0.007)。

临床怎么用

  • 房颤合并急性冠脉综合征或PCI后接受P2Y12抑制剂的患者,优先选择阿哌沙班而非维生素K拮抗剂,肾功能不全者同样获益。
  • 应避免在无明确指征时加用阿司匹林,因其在各肾功能类别均增加出血风险,肾功能正常者出血增幅更显著。

局限性

  • 肌酐清除率<30 mL/min患者被排除,结果不适用于该人群。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the AUGUSTUS trial (An Open-Label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), apixaban resulted in less bleeding and fewer hospitalizations than vitamin K antagonists, and aspirin caused more bleeding than placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention treated with a P2Y12 inhibitor. We evaluated the risk-benefit balance of antithrombotic therapy according to kidney function. METHODS: In 4456 patients, the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula was used to calculate baseline estimated glomerular filtration rate (eGFR). The effect of apixaban versus vitamin K antagonists and aspirin versus placebo was assessed across kidney function categories by using Cox models. The primary outcome was International Society on Thrombosis and Haemostasis major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and ischemic events (death, stroke, myocardial infarction, stent thrombosis [definite or probable], or urgent revascularization). Creatinine clearance <30 mL/min was an exclusion criterion in the AUGUSTUS trial. RESULTS: Overall, 30%, 52%, and 19% had an eGFR of >80, >50 to 80, and 30 to 50 mL·min-1·1.73 m-2, respectively. At the 6-month follow-up, a total of 543 primary outcomes of bleeding, 1125 death or hospitalizations, and 282 ischemic events occurred. Compared with vitamin K antagonists, patients assigned apixaban had lower rates for all 3 outcomes across most eGFR categories without significant interaction. The absolute risk reduction with apixaban was most pronounced in those with an eGFR of 30 to 50 mL·min-1·1.73 m-2 for bleeding events with rates of 13.1% versus 21.3% (hazard ratio, 0.59; 95% CI, 0.41-0.84). Patients assigned aspirin had a higher risk of bleeding in all eGFR categories with an even greater increase among those with eGFR >80 mL·min-1·1.73 m-2: 16.6% versus 5.6% (hazard ratio, 3.22; 95% CI, 2.19-4.74; P for interaction=0.007). The risk of death or hospitalization and ischemic events were comparable to aspirin and placebo across eGFR categories with hazard ratios ranging from 0.97 (95% CI, 0.76-1.23) to 1.28 (95% CI, 1.02-1.59) and from 0.75 (95% CI, 0.48-1.17) to 1.34 (95% CI, 0.81-2.22), respectively. CONCLUSIONS: The safety and efficacy of apixaban was consistent irrespective of kidney function, compared with warfarin, and in accordance with the overall trial results. The risk of bleeding with aspirin was consistently higher across all kidney function categories. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02415400.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Hijazi Z, Alexander JH, Li Z, et al. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2021. PMID: 33461308. doi:10.1161/CIRCULATIONAHA.120.051020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。